Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 1024-1028

  Snydman, David R ^a,b   Jacobus, Nilda V ^a   McDermott, Laura A ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaerobic pathogens; Bacterial metalloproteases; Novel peptide deformylase inhibitor; Peptide deformylase inhibitor (PDF)

Indexed keywords

ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; CEFOXITIN; CLINDAMYCIN; GARENOXACIN; IMIPENEM; LINEZOLID; METICILLIN; MOXIFLOXACIN; NVP LMB 415; QUINOLONE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BACTEROIDES; BACTEROIDES DISTASONIS; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; CLOSTRIDIACEAE; CLOSTRIDIUM; CLOSTRIDIUM INNOCUUM; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM RAMOSUM; CLOSTRIDIUM SEPTICUM; CONTROLLED STUDY; DRUG MECHANISM; ENTEROCOCCUS; FREQUENCY ANALYSIS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PEPTOSTREPTOCOCCUS; PROPIONIBACTERIUM ACNES; SPECIES DIFFERENCE; STREPTOCOCCUS;

AMIDOHYDROLASES; BACTEROIDES FRAGILIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES;

EID: 21244491572     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki107     Document Type: Article

References (7)

1. Snydman, D. R., Jacobus, N. V., McDermott, L. A. et al. (2002). National survey on the susceptibility of B. fragifis group: report and analysis of trends for 1997-2000. Clinical Infectious Diseases 35, Suppl. 1, S126-34.
2. Snydman, D. R., Jacobus, N. V., McDermott, L. A. et al. (2002). In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrobial Agents and Chemotherapy 46, 3276-9.
3. Ryder, N. S., Kubik, B., Mlineritsch, W. et al. (2002). NVP-PDF386 (VRC4887), a new antibacterial peptide deformylase inhibitor with potent in vitro activity against drug-resistant organisms, In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract F-1671, p. 221. American Society for Microbiology, Washington, DC, USA.
4. Wu, C., Chen, D., Ni, Z. J., et al. (2002). Identification of alkylsuccinate-proline hydroxamates as peptide deformylase (PDF) inhibitors through integrated combinatorial and medicinal chemistry. In Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract F1668, p. 220. American Society for Microbiology, Washington, DC, USA.
5. Jones, R. N., Moet, G. J., Sader, H. S. et al. (2004). Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone- resistant or streptogramin-resistant Gram-positive organism isolates. Journal of Antimicrobial Chemotherapy 53, 804-7.
6. National Committee for Clinical Laboratory Standards. (2001). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Fifth Edition: Approved Standard M11-A5, M11-A5. NCCLS, Villanova, PA, USA.
7. Jousimies-Somer, H. R., Summanem, P., Citron, D. M., et al. (2002). Wadsworth-KTL Anaerobic Bacteriology Manual, 6th edn. Star Publishing Co, Belmont, CA, USA.